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and as Maintenance Therapy in Ovarian Cancer
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M. Friedlander, A. Okamoto, K.N. Moore, N. Efrat Ben‑Baruch, T.L. Werner,
N.G. Cloven, A. Oaknin, P.A. DiSilvestro, M.A. Morgan, J.-H. Nam, C.A. Leath III,
S. Nicum, A.R. Hagemann, R.D. Littell, D. Cella, S. Baron‑Hay, J. Garcia‑Donas,
M. Mizuno, K. Bell‑McGuinn, D.M. Sullivan, B.A. Bach, S. Bhattacharya,
C.K. Ratajczak, P.J. Ansell, M.H. Dinh, C. Aghajanian, and M.A. Bookman

A BS T R AC T
BACKGROUND

Data are limited regarding the use of poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by
maintenance as initial treatment in patients with high-grade serous ovarian carcinoma.
METHODS

In an international, phase 3, placebo-controlled trial, we assessed the efficacy of
veliparib added to first-line induction chemotherapy with carboplatin and paclitaxel
and continued as maintenance monotherapy in patients with previously untreated
stage III or IV high-grade serous ovarian carcinoma. Patients were randomly assigned
in a 1:1:1 ratio to receive chemotherapy plus placebo followed by placebo maintenance
(control), chemotherapy plus veliparib followed by placebo maintenance (veliparib
combination only), or chemotherapy plus veliparib followed by veliparib maintenance (veliparib throughout). Cytoreductive surgery could be performed before initiation or after 3 cycles of trial treatment. Combination chemotherapy was 6 cycles,
and maintenance therapy was 30 additional cycles. The primary end point was
investigator-assessed progression-free survival in the veliparib-throughout group
as compared with the control group, analyzed sequentially in the BRCA-mutation cohort, the cohort with homologous-recombination deficiency (HRD) (which included
the BRCA-mutation cohort), and the intention-to-treat population.

The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr.
Coleman at the University of Texas M.D.
Anderson Cancer Center, 1155 Pressler
Dr., Houston, TX 77030, or at r coleman@
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This article was published on September 28,
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DOI: 10.1056/NEJMoa1909707
Copyright © 2019 Massachusetts Medical Society.

RESULTS

A total of 1140 patients underwent randomization. In the BRCA-mutation cohort,
the median progression-free survival was 34.7 months in the veliparib-throughout
group and 22.0 months in the control group (hazard ratio for progression or
death, 0.44; 95% confidence interval [CI], 0.28 to 0.68; P<0.001); in the HRD cohort, it was 31.9 months and 20.5 months, respectively (hazard ratio, 0.57; 95 CI,
0.43 to 0.76; P<0.001); and in the intention-to-treat population, it was 23.5 months
and 17.3 months (hazard ratio, 0.68; 95% CI, 0.56 to 0.83; P<0.001). Veliparib led
to a higher incidence of anemia and thrombocytopenia when combined with chemotherapy as well as of nausea and fatigue overall.
CONCLUSIONS

Across all trial populations, a regimen of carboplatin, paclitaxel, and veliparib induction therapy followed by veliparib maintenance therapy led to significantly longer
progression-free survival than carboplatin plus paclitaxel induction therapy alone. The
independent value of adding veliparib during induction therapy without veliparib
maintenance was less clear. (Funded by AbbVie; VELIA/GOG-3005 ClinicalTrials.gov
number, NCT02470585.)
n engl j med 381;25
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ince the introduction of paclitaxel
in 1996,1 efforts to augment the efficacy of
treatment in patients with advanced-stage
ovarian cancer have yielded limited success. The
introductions of weekly paclitaxel therapy, intraperitoneal chemotherapy, and bevacizumab therapy are recognized alterations that are considered
to be acceptable as primary therapy.2-5 Delayed
cytoreductive surgery after neoadjuvant chemotherapy has also become increasingly popular,
given the evidence of noninferiority to primary
debulking surgery that has been shown in randomized, controlled trials.6-8 Nevertheless, progressive disease develops in more than 75% of
patients within 3 years.9 New agents and approaches are needed.
Poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors have efficacy as single
agents in the treatment of recurrent ovarian cancer and as maintenance therapy after patients have
had a response to platinum-based therapy.10-18
Olaparib,12,15 rucaparib,14,16 and niraparib13 have
been approved for indications in high-grade epithelial ovarian cancer, but only olaparib has been
approved as maintenance therapy in patients with
deleterious BRCA mutations after a response to
first-line chemotherapy.17 Combining PARP inhibitors with chemotherapy has been challenging because of hematologic toxic effects that result in
substantial dose reductions.19 Veliparib is an oral
PARP inhibitor20 that has shown activity as a
single agent in early-phase trials and that can be
combined with standard chemotherapy doses.21-24
Approximately 20% of ovarian carcinomas have
germline (15%) or somatic (5%) BRCA1 or BRCA2
mutations,25 and up to 30% more have genomic
alterations resulting in homologous-recombination
deficiency (HRD).26 These alterations increase tumor susceptibility to agents including platinum
and PARP inhibitors.25-29 We hypothesized that
veliparib added to platinum-based chemotherapy
and continued as maintenance therapy would prolong progression-free survival. Here, we report results from VELIA/GOG-3005, a randomized, placebo-controlled trial of veliparib in patients with
newly diagnosed, high-grade serous ovarian carcinoma.
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epithelial ovarian, fallopian tube, or primary peritoneal carcinoma of International Federation of
Gynecology and Obstetrics stage III or IV were
included in the trial (Table S1 in the Supplementary Appendix, available with the full text of this
article at NEJM.org).30 Additional eligibility criteria
are listed in the protocol (available at NEJM.org).
The submission of blood and tumor-tissue
samples for central assessment of germline BRCA,
tissue-based (included somatic) BRCA, and homologous-recombination status was required. The
BRCA-mutation cohort was defined as patients who
had deleterious or suspected deleterious germline
or tissue-based mutations, as determined by the
Myriad BRACAnalysis CDx or myChoice HRD
CDx assay, respectively, in BRCA1 or BRCA2. The
cohort of patients with tumors that had HRD
consisted of patients who had tumors that were
BRCA-mutated or had HRD according to the myChoice assay (on which a score of ≥33 was considered to indicate HRD status, and a score of
<33 was considered to indicate non-HRD status;
the threshold score was revised from 42, after
several retrospective analyses of previous clinical
trials, to increase the sensitivity of detecting a
response to PARP inhibitors).31-33 The intentionto-treat population comprised all the patients who
had undergone randomization. For exploratory
analyses, the cohort of patients with nonmutated BRCA status consisted of patients with known
BRCA status and no germline or tissue-based BRCA
mutations. Patients whose tumors had non-HRD
status had no genetic evidence of HRD.
Trial Design and Treatments

This phase 3, double-blind trial was conducted
at 202 sites in 10 countries. Randomization in
the entire population was stratified according to
the timing of surgery and residual disease after
primary surgery, the paclitaxel schedule, stage of
disease, geographic region, and germline BRCA
status as described in the protocol. Cytoreductive surgery could be performed before the initiation of trial treatment (primary) or after three
cycles of trial treatment (interval). The weekly or
every-3-week paclitaxel schedule and the choice
of primary or interval cytoreductive surgery were
determined at the discretion of the investigator.
The germline BRCA status was added as a stratifiMe thods
cation factor after 655 patients (57%) had enrolled
Patients
in order to counteract an imbalance regarding
Women at least 18 years of age who had received BRCA-mutation status that was noted by the inan initial histologic diagnosis of high-grade serous dependent data and safety monitoring committee.
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Each trial regimen consisted of 36 cycles lasting 21 days each, including 6 cycles of chemotherapy and 30 cycles of maintenance therapy.
Chemotherapy consisted of carboplatin (given at
an area under the curve [AUC] of 6 mg per milli
liter per minute, every 3 weeks) and paclitaxel
(175 mg per square meter of body-surface area,
administered every 3 weeks, or 80 mg per square
meter, administered weekly). Patients were randomly assigned in a 1:1:1 ratio to one of the following three groups: the control group (in which
patients received chemotherapy plus placebo
followed by placebo maintenance); the veliparibcombination-only group (in which patients received chemotherapy plus veliparib followed by
placebo maintenance); or the veliparib-throughout
group (in which patients received chemotherapy
plus veliparib followed by veliparib maintenance).
During chemotherapy, patients received veliparib at a dose of 150 mg orally or matching placebo
twice daily.24 Patients who completed chemother
apy without disease progression received singleagent veliparib at a dose of 300 mg or matching
placebo twice daily for 2 weeks (transition period)
and then veliparib at a dose of 400 mg or matching
placebo twice daily if the dose in the transition
period was not associated with limiting side effects.
End Points and Assessments

assigned treatment after the occurrence of disease progression. Crossover to veliparib was not
allowed in the trial.
The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy
Ovarian Symptom Index–18 (NFOSI-18), which
evaluates nine symptoms related to disease or
treatment.35 This questionnaire was administered
at protocol-defined intervals until disease progression or up to 2 years after the receipt of the first
dose, whichever was later. Scores range from 0 to
36, with higher scores indicating a lower burden
of symptoms. A 3-point difference was defined
as clinically meaningful.36 Adverse events were
categorized according to preferred terms in the
Medical Dictionary for Regulatory Activities, version
21.1, and were graded according to the National
Cancer Institute Common Terminology Criteria
for Adverse Events, version 4.03.
Oversight

The trial protocol was approved by the institutional review boards at the investigational sites;
the statistical analysis plan and all amendments
are provided with the protocol. The trial was
conducted according to the International Conference on Harmonisation Good Clinical Practice guidelines, regulations governing clinical
study conduct, and ethical principles with their
origin in the Declaration of Helsinki. All the
patients provided written informed consent.
The trial was designed and conducted by the
Gynecologic Oncology Group and the sponsor
(AbbVie). An independent data and safety monitoring committee reviewed unblinded safety
data and provided recommendations for continuation or termination. All the authors had
access to the data and vouch for the accuracy
and completeness of the data and for the fidelity of the trial to the protocol. The manuscript
was written by the authors, with medical writing assistance funded by the sponsor. Representatives of the sponsor also participated in
the trial conduct, the analysis and interpretation of the data, and the writing and review of
the manuscript. The authors and sponsor made
the decision to submit the manuscript for submission for publication.

The primary end point was investigator-assessed
progression-free survival in the veliparibthroughout group as compared with the control
group, analyzed sequentially in the BRCA-mutation cohort, the HRD cohort, and the intentionto-treat population. Secondary end points were
overall survival in the veliparib-throughout group
as compared with the control group, progressionfree survival and overall survival in the veliparibcombination-only group as compared with the
control group, and the Disease Related Symptom
score (see below) in the BRCA-mutation cohort, the
HRD cohort, and the intention-to-treat population.
Tumor assessments according to the Response
Evaluation Criteria in Solid Tumors, version 1.1,
occurred at baseline and at protocol-defined intervals until the occurrence of imaging-based
progression as assessed by the investigator.34 Patients undergoing interval surgery had a tumor
baseline reassessment after surgery. After the occurrence of investigator-assessed progression, data
on survival, subsequent therapy, and new-onset Statistical Analysis
cancer were collected until death or loss to fol- Efficacy analyses were performed in three selow-up. Investigators could be made aware of the quentially inclusive populations: the BRCA-mutan engl j med 381;25
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tion cohort, the HRD cohort (which included the
BRCA-mutation cohort), and the intention-to-treat
population. All the patients who had received at
least one dose of veliparib or placebo were included in the safety analyses. The data-cutoff date
for the primary analysis was May 3, 2019.
The trial sought to enroll 1100 patients and
was powered to test progression-free survival
and overall survival in the intention-to-treat
population and the BRCA-mutation cohort. On
the basis of emerging efficacy data regarding
patients with HRD tumors,13,14,16,37 the protocol
was amended to add testing variables for the
primary and secondary end points within this
cohort. The database lock occurred when the
protocol-specified number of progression-free
survival events in the control group plus the veliparib-throughout group was confirmed on independent analysis of the statistical data.
A two-sided P value of 0.05 or less was considered to indicate statistical significance in
analyses that followed a hierarchical testing sequence. Specifically, progression-free survival in
the veliparib-throughout group and the control
group was first compared in the BRCA-mutation
cohort, then in the HRD cohort, and then in the
intention-to-treat population. This analysis was
to be followed by an evaluation of overall survival
(once a sufficient number of events had accrued)
in the veliparib-throughout group and the control
group in each of the three populations. The testing sequence was to end at the first test that did
not meet the threshold for significance. Progression-free survival in the veliparib-combinationonly group as compared with the control group
would be formally tested if the comparisons for
overall survival met the threshold for significance.
Distributions of progression-free survival and
overall survival in each group were estimated
with the use of the Kaplan–Meier method. Progression-free survival in the veliparib-throughout group or the veliparib-combination-only group
was compared with the control group by a logrank test, stratified according to residual disease
status and disease stage in all the trial populations, as well as according to choice of the paclitaxel regimen and BRCA-mutation status in the
intention-to-treat population. Hazard ratios in
the analyses of progression-free survival and
overall survival were estimated by means of a
Cox model stratified according to the same fac2406
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tors as those used in the log-rank test. The mean
change from baseline in the Disease Related
Symptom scores was compared with the use of
a mixed-model, repeated-measures method.

R e sult s
Patients

From July 2015 through July 2017, a total of 1140
patients underwent randomization. BRCA-mutation and homologous-recombination status was
determined in 91% and 88% of the patients, respectively. A total of 298 patients (26%) were
included in the BRCA-mutation cohort (214 patients [19%] had a germline BRCA mutation, and
84 [7%] had a tissue-based BRCA mutation), and
627 patients (55%) were included in the HRD
cohort (298 patients [26%] had tumors that had
HRD and were BRCA-mutated, and 329 patients
[29%] had tumors that had HRD with nonmutated BRCA). A total of 1124 patients received at
least one dose of trial therapy (Fig. 1).
Key demographic and clinical characteristics
of the patients are shown in Table 1. The characteristics of the patients in the BRCA-mutation
cohort and the HRD cohort are shown in Tables
S2 and S3, respectively.
Efficacy

Primary End Point of Progression-free Survival

At the time of the database lock, the median
duration of follow-up was 28 months. The primary
efficacy end point of progression-free survival in
the veliparib-throughout group as compared with
the control group was significantly prolonged in
all three cohorts (presented here in order of testing hierarchy). The median progression-free survival in the BRCA-mutation cohort was 34.7 months
in the veliparib-throughout group and 22.0 months
in the control group (hazard ratio for disease progression or death, 0.44; 95% confidence interval
[CI], 0.28 to 0.68; P<0.001); in the HRD cohort,
the corresponding duration was 31.9 months
and 20.5 months (hazard ratio, 0.57; 95% CI,
0.43 to 0.76; P<0.001); and in the intention-totreat population, the corresponding duration was
23.5 months and 17.3 months (hazard ratio,
0.68; 95% CI, 0.56 to 0.83; P<0.001) (Fig. 2). The
number of events of disease progression or deaths
and the estimates of progression-free survival at
4.5 months after randomization (approximate
end of the combination phase) are provided for
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1396 Patients were assessed for eligibility

256 Were excluded

1140 Underwent randomization

375 Were assigned to the control group
and were included in efficacy analysis

383 Were assigned to the veliparibcombination-only group and were
included in efficacy analysis

382 Were assigned to the veliparibthroughout group and were
included in efficacy analysis

371 Received treatment and were
included in safety analysis

376 Received treatment and were
included in safety analysis

377 Received treatment and were
included in safety analysis

355 Discontinued trial drug
188 Had progressive disease
76 Completed treatment
10 Had adverse event related
to progression
22 Had adverse event unrelated
to progression
24 Withdrew consent for receiving
trial drug
22 Were withdrawn by investigator
9 Had other reason
3 Underwent randomization but
never received trial drug
1 Was lost to follow-up

363 Discontinued trial drug
194 Had progressive disease
70 Completed treatment
8 Had adverse event related
to progression
36 Had adverse event unrelated
to progression
23 Withdrew consent for receiving
trial drug
19 Were withdrawn by investigator
6 Had other reason
5 Underwent randomization but
never received trial drug
2 Were lost to follow-up

348 Discontinued trial drug
119 Had progressive disease
69 Completed treatment
3 Had adverse event related
to progression
82 Had adverse event unrelated
to progression
40 Withdrew consent for receiving
trial drug
20 Were withdrawn by investigator
8 Had other reason
5 Underwent randomization but
never received trial drug
2 Were lost to follow-up

Figure 1. Randomization and Treatment.
Patients were randomly assigned in a 1:1:1 ratio to one of the following three groups: control group (in which patients received chemotherapy plus placebo followed by placebo maintenance); the veliparib-combination-only group
(in which patients received chemotherapy plus veliparib followed by placebo maintenance); or the veliparib-throughout group (in which patients received chemotherapy plus veliparib followed by veliparib maintenance). The primary
reasons for the discontinuation of veliparib or placebo are shown.

each of the trial cohorts in Figure S1 and Table tion-only group as compared with the control
S4, respectively.
group has not been performed.
At the time of the database lock, the median
Secondary End Points
progression-free survival in the veliparib-combiAt the time of this report, the data regarding nation-only group and control group in the three
overall survival were not sufficiently mature in populations was as follows. In the BRCA-mutathe BRCA-mutation cohort, the HRD cohort, and tion cohort, the median progression-free surthe intention-to-treat population, with percentages vival was 21.1 months in the veliparib-combinaof required end points of 21%, 24%, and 49%, tion-only group and 22.0 months in the control
respectively. Because of the testing hierarchy, group (hazard ratio for progression or death,
overall survival in the veliparib-throughout group 1.22; 95% CI, 0.82 to 1.80); in the HRD cohort,
as compared with the control group cannot be the corresponding duration was 18.1 months
tested until a sufficient number of events have and 20.5 months (hazard ratio, 1.10; 95% CI, 0.86
occurred, so formal hypothesis testing of pro- to 1.41); and in the intention-to-treat population,
gression-free survival in the veliparib-combina- the corresponding duration was 15.2 months and
n engl j med 381;25
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Table 1. Demographic and Clinical Characteristics of the Patients.*

Characteristic
Age
Median (range) — yr
Distribution — no. (%)
<65 yr
≥65 yr
Geographic region — no. (%)
North America
Japan
Other region
ECOG performance-status score — no./total no. (%)†
0
1
2
Stage of disease — no./total no. (%)
Stage III
Stage IV
Surgery received‡
Primary
Interval
None
Residual disease after primary surgery — no./total no. (%)
No residual disease§
Microscopic residual disease only§
Any residual disease
Residual disease after interval surgery — no./total no. (%)¶
No residual disease§
Microscopic residual disease only§
Any residual disease
Paclitaxel regimen — no./total no. (%)
Weekly
Every 3 wk
BRCA-mutation status — no./total no. (%)‖
Deleterious mutation
No deleterious mutation
Homologous-recombination deficiency — no./total no. (%)
Yes
No

Control Group
(N = 375)

Veliparib-CombinationOnly Group
(N = 383)

Veliparib-Throughout
Group
(N = 382)

62 (33–86)

62 (22–88)

62 (30–85)

233 (62)
142 (38)

226 (59)
157 (41)

228 (60)
154 (40)

266 (71)
23 (6)
86 (23)

261 (68)
30 (8)
92 (24)

267 (70)
25 (7)
90 (24)

226/371 (61)
138/371 (37)
7/371 (2)

210/376 (56)
157/376 (42)
9/376 (2)

224/377 (59)
141/377 (37)
12/377 (3)

292/374 (78)
82/374 (22)

288/382 (75)
94/382 (25)

295/382 (77)
87/382 (23)

250 (67)
107 (29)
18 (5)

253 (66)
114 (30)
16 (4)

261 (68)
99 (26)
22 (6)

116/250 (46)
58/250 (23)
76/250 (30)

118/253 (47)
46/253 (18)
89/253 (35)

124/261 (48)
54/261 (21)
83/261 (32)

50/103 (49)
22/103 (21)
31/103 (30)

46/110 (42)
30/110 (27)
34/110 (31)

  45/96 (47)
  24/96 (25)
  27/96 (28)

193/372 (52)
179/372 (48)

203/381 (53)
178/381 (47)

190/379 (50)
189/379 (50)

92/346 (27)
254/346 (73)

98/341 (29)
243/341 (71)

108/353 (31)
245/353 (69)

207/331 (63)
124/331 (37)

206/329 (63)
123/329 (37)

214/339 (63)
125/339 (37)

*	Patients were randomly assigned in a 1:1:1 ratio to one of the following three groups: the control group (in which patients received chemotherapy plus placebo followed by placebo maintenance); the veliparib-combination-only group (in which patients received chemotherapy
plus veliparib followed by placebo maintenance); or the veliparib-throughout group (in which patients received chemotherapy plus veliparib
followed by veliparib maintenance). Stratification factors included geographic region, disease stage (International Federation of Gynecology
and Obstetrics stage III or IV disease), timing of surgery received (primary or interval), residual disease status after primary surgery, and paclitaxel regimen. Data regarding geographic region, disease stage, timing of surgery received, residual disease status after primary or interval surgery, and paclitaxel regimen were as reported in the electronic data-capture system.
†	Eastern Cooperative Oncology Group (ECOG) performance-status scores are assessed on a 5-point scale, with higher scores indicating greater disability.
‡	All the patients underwent randomization with the intention of undergoing cytoreductive surgery. Some patients did not undergo the planned
interval surgery.
§	The subgroups of patients with microscopic residual disease and those with no residual disease were combined in a “no macroscopic residual disease” category (not listed here) in the subgroup analyses of progression-free survival.
¶	Data on any residual disease after interval surgery were missing for 4 of 107 patients in the control group, for 4 of 114 in the veliparib-combination-only group, and for 3 of 99 in the veliparib-throughout group.
‖	Deleterious BRCA mutations included germline and tissue-based BRCA1 and BRCA2 mutations.
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A Progression-free Survival in Intention-to-Treat Population
No. of Events/
No. of Patients (%)

Median
Progression-free
Survival (95% CI)
mo

Progression-free
Survival at 10 Mo
(95% CI)

191/382 (50)
237/375 (63)

23.5 (19.3–26.3)
17.3 (15.1–19.1)

84 (80–88)
77 (72–81)

Patients Alive without Disease
Progression (%)

Veliparib
Control
100
90
80
70
60
50
40
30
20
10
0

Progression-free
Survival at 24 Mo
(95% CI)
%
48 (42–53)
34 (29–39)

Hazard ratio for progression or death, 0.68 (95% CI, 0.56–0.83)
P<0.001

Veliparib throughout
Control
0

2

4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

38

40

42

44

55
36

38
21

26
16

19
10

7
3

2
0

1
—

0
—

Months since Randomization
No. at Risk
Veliparib
Control

382 352 337 329 308 275 253 228 208 192 172 153 111 95
375 356 340 328 297 260 236 202 172 153 143 119 84 70

76
55

Patients Alive without Disease
Progression (%)

B Progression-free Survival in Trial Cohorts
100
90
80
70
60
50
40
30
20
10
0

BRCA-mutation cohort: Hazard ratio, 0.44 (95% CI, 0.28–0.68); P<0.001
HRD cohort: Hazard ratio, 0.57 (95% CI, 0.43–0.76); P<0.001

BRCA-mutation cohort
Veliparib
Control
HRD cohort
Veliparib
Control
0

2

4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

38

40

42

44

Months since Randomization
No. at Risk

BRCA-mutation
cohort
Veliparib
Control
HRD cohort
Veliparib
Control

108 102
92 90

99
89

97
88

95
84

90
80

65 53
38 29

45
24

38
19

30
13

21
6

14
4

9
2

5
0

1
—

1
—

0
—

214 203 195 191 182 167 161 150 140 130 121 109 82
207 199 196 191 183 170 158 134 119 104 97 79 55

72
47

58
34

44
22

30
11

19
9

14
4

5
2

1
0

1
—

0
—

88
74

82
63

80
57

76
50

73
46

Figure 2. Kaplan–Meier Estimates of Progression-free Survival in the Veliparib-Throughout Group and Control Group.
Distributions were estimated by means of the Kaplan–Meier method in the intention-to-treat population (Panel A)
and in the cohorts of patients with BRCA-mutated tumors or with tumors that had homologous-recombination deficiency (HRD) (Panel B), with the veliparib-throughout group compared with the control group (primary end point).
Progression-free survival was compared between the trial-treatment groups by the stratified log-rank test. Hazard
ratios were estimated by a Cox model with stratification according to the same factors as were used in the log-rank
test. Kaplan–Meier estimates of the percentages of patients who were alive without disease progression at 10 months
(approximately 6 months after the completion of chemotherapy) and at 24 months (end of trial-defined therapy) in
each population are shown. The dashed line indicates the median, and tick marks indicate censored data.
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17.3 months (hazard ratio, 1.07; 95% CI, 0.90 to these analyses were directionally consistent with
1.29) (Fig. S2).
those of the primary analysis in the intention-totreat population.
Exploratory Analyses
Assessment in the veliparib-throughout and
Analyses of progression-free survival in subgroups control groups in the subgroup of patients with
that were defined according to potential prognos- nonmutated BRCA (which included patients with
tic factors is shown in Figure 3. The findings of HRD tumors with nonmutated BRCA) and those
Subgroup

Veliparib

Control

Hazard Ratio for Disease Progression or Death (95% CI)

no. of patients with events/total no.
All patients
Age
<65 yr
≥65 yr
Race
White
Asian
Other
ECOG performance-status score
0
≥1
Disease stage
III
IV
Paclitaxel regimen
Weekly
Every 3 wk
Surgery received
Primary
Interval
Residual disease after primary surgery
Macroscopic residual disease
No macroscopic residual disease
Residual disease after interval surgery
Macroscopic residual disease
No macroscopic residual disease
Mutation status
BRCA1
BRCA2
Germline BRCA
Tissue-based BRCA
Nonmutated BRCA
HRD-positive
HRD-negative

191/382

237/375

0.70 (0.58–0.84)

110/228
81/154

155/233
82/142

0.65 (0.50–0.82)
0.77 (0.57–1.05)

158/300
21/56
12/26

194/299
35/59
8/17

0.70 (0.57–0.86)
0.50 (0.29–0.87)
1.57 (0.63–3.97)

113/224
78/153

135/226
102/145

0.72 (0.56–0.93)
0.66 (0.49–0.89)

142/295
49/87

183/292
54/82

0.67 (0.54–0.84)
0.79 (0.54–1.17)

92/190
99/189

125/193
112/179

0.65 (0.50–0.85)
0.73 (0.55–0.95)

126/261
56/99

149/250
78/107

0.72 (0.57–0.92)
0.64 (0.45–0.90)

42/83
84/178

50/76
99/174

0.60 (0.40–0.91)
0.77 (0.58–1.04)

23/27
33/69

23/31
53/72

1.12 (0.62–2.00)
0.52 (0.34–0.81)

26/78
8/30
27/80
7/28
142/245
87/214
80/125

36/59
13/31
36/63
15/29
171/254
124/207
89/124

0.38 (0.23–0.63)
0.64 (0.27–1.56)
0.50 (0.30–0.82)
0.35 (0.14–0.87)
0.80 (0.64–1.00)
0.58 (0.44–0.76)
0.81 (0.60–1.09)
0.1

1.0

Veliparib Better

10.0

Control Therapy Better

Figure 3. Subgroup Analysis of Progression-free Survival.
The hazard ratio in the analysis of progression-free survival is for the comparison of the veliparib-throughout group with the control
group. The hazard ratios presented here are from an unstratified Cox proportional-hazards model. Stratification factors included disease
stage, paclitaxel regimen, surgery received, and residual disease status after primary surgery. Race was reported by the patient. Eastern
Cooperative Oncology Group (ECOG) performance-status scores are assessed on a 5-point scale, with higher scores indicating greater
disability. Disease stage was assessed as International Federation of Gynecology and Obstetrics stage III or IV disease. No macroscopic
residual disease was defined as either “no residual disease” or “microscopic residual disease only” after surgery, as reported in the electronic data-capture system. Data on BRCA-mutation status were missing for 29 patients in the veliparib-throughout group and for 29 in
the control group; data on HRD status were missing for 43 and 44, respectively.
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in the non-HRD cohort (patients with true nonmutated BRCA status) showed hazard ratios of
0.80 (95% CI, 0.64 to 0.997) and 0.81 (95% CI,
0.60 to 1.09), respectively (Fig. S3). The lack of
data maturity regarding events of progression or
death with a second therapy precludes a meaningful analysis at this time, with 42% or less of
the patients in any population having reported
progression while receiving a second therapy.
In the intention-to-treat population, 191 patients (98 in the veliparib-throughout group and
93 in the control group) had measurable residual disease after primary debulking surgery from
which the percentage of patients with an objective response could be assessed after six cycles
of chemotherapy. In this exploratory analysis,
84% of the patients in the veliparib-throughout
group had a response, as compared with 74% of
those in the control group (Table S5).
Safety

The relative dose intensities of carboplatin and
paclitaxel were similar across treatment groups
and all the cohorts (the BRCA-mutation cohort,
the HRD cohort, and the intention-to-treat population). In the intention-to-treat population, the
veliparib-throughout group and the control group
received 84% and 91%, respectively, of the planned
carboplatin doses; 84% and 90% of the planned
weekly doses of paclitaxel; and 92% and 98% of
the planned every-3-week doses of paclitaxel. The
median numbers of cycles of carboplatin and
paclitaxel were the same across all the groups and
all the cohorts. Details are provided in Table S6.
In the intention-to-treat population, the proportion of patients who had an adverse event
during treatment (i.e., events reported during
trial treatment or within 30 days after the discontinuation of veliparib or placebo) were similar in
the veliparib-throughout group and the control
group. However, a higher percentage of patients
in the veliparib-throughout group than in the
control group had thrombocytopenia (Table 2).
The most common adverse event during treatment that was reported in the veliparib-throughout group was nausea (in 80% of the patients in
this group), with most events (90%) being of
grade 1 or 2. One event of myelodysplastic syndrome was reported in the veliparib-combination-only group, and one event of acute myeloid
leukemia was reported in the veliparib-through-

n engl j med 381;25

out group. The patient with myelodysplastic syndrome had a germline BRCA1 mutation. The numbers and proportions of patients in whom adverse
events during treatment were reported in the
combination phase or in the maintenance phase
are shown in Tables S7 and S8, respectively.
The percentages of patients who had a reduction in the dose of veliparib or placebo or an
interruption because of an adverse event were
higher in the veliparib-throughout group than in
the control group during the combination phase
(dose reductions in 6% and 2% of the patients,
respectively, and interruptions in 58% and 39%)
and the maintenance phase (dose reductions in
24% and 4%, respectively, and interruptions in
41% and 19%) (Table S9). In the combination
phase, 11% or less of the patients had an adverse
event leading to the discontinuation of veliparib
or placebo in any group (Table S10). In the maintenance phase, the percentage of patients who
discontinued veliparib or placebo owing to an adverse event was 19% in the veliparib-throughout
group and 6% in the control group. The most
common adverse event leading to the discontinuation of veliparib therapy was nausea (in 8% of
patients).
Health-Related Quality-of-Life Assessments

A total of 86% of the patients had greater than
90% adherence to the completion of patient-reported outcome instruments during trial therapy; 60%
of the patients had greater than 80% adherence
after therapy discontinuation. Adherence was balanced among the groups. In the BRCA-mutation
cohort, the HRD cohort, and the intention-to-treat
population, the mean change from baseline in the
NFOSI-18 Disease Related Symptom scores increased over time (indicating improvement), particularly after chemotherapy was completed (cycle
7 and beyond). The differences in the mean change
from baseline in scores between treatment groups
were small (range, 0.0 to 2.1) and were not considered to be clinically significant (Fig. S4).

Discussion
This phase 3 trial shows significantly longer
progression-free survival with veliparib added to
standard first-line chemotherapy and continued
as maintenance therapy than with chemotherapy
alone among patients with advanced-stage, high-
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Table 2. Adverse Events.*
Control Group
(N = 371)

Event

Any Grade

Veliparib-Combination-Only Group
(N = 376)

Grade 3 or 4

Any Grade

Grade 3 or 4

Veliparib-Throughout Group
(N = 377)
Any Grade

Grade 3 or 4

329 (88)

377 (100)

332 (88)

number of patients (percent)
Any

371 (100)

285 (77)

376 (100)

Nausea
Neutropenia

251 (68)

10 (3)

269 (72)

15 (4)

302 (80)

31 (8)

251 (68)

183 (49)

281 (75)

232 (62)

284 (75)

218 (58)

Fatigue

222 (60)

12 (3)

235 (62)

18 (5)

259 (69)

31 (8)

Peripheral sensory neuropathy

256 (69)

9 (2)

236 (63)

7 (2)

242 (64)

9 (2)

Anemia

195 (53)

97 (26)

245 (65)

153 (41)

240 (64)

144 (38)

Thrombocytopenia

122 (33)

30 (8)

225 (60)

115 (31)

219 (58)

105 (28)

Alopecia

215 (58)

2 (1)

216 (57)

0

197 (52)

0

Vomiting

132 (36)

9 (2)

133 (35)

14 (4)

186 (49)

15 (4)

Diarrhea

152 (41)

9 (2)

140 (37)

11 (3)

166 (44)

8 (2)

Constipation

160 (43)

2 (1)

181 (48)

7 (2)

165 (44)

2 (1)

Abdominal pain

118 (32)

14 (4)

113 (30)

13 (3)

127 (34)

17 (5)

Leukopenia

89 (24)

34 (9)

87 (23)

44 (12)

112 (30)

66 (18)

Decreased appetite

85 (23)

3 (1)

81 (22)

3 (1)

111 (29)

7 (2)

Insomnia

87 (23)

0

121 (32)

1 (<1)

110 (29)

3 (1)

Arthralgia

123 (33)

4 (1)

106 (28)

1 (<1)

106 (28)

4 (1)

Dizziness

89 (24)

0

81 (22)

2 (1)

98 (26)

4 (1)

Headache

97 (26)

3 (1)

91 (24)

2 (1)

97 (26)

1 (<1)

Hypomagnesemia

98 (26)

10 (3)

94 (25)

5 (1)

84 (22)

3 (1)

Dyspnea

76 (20)

3 (1)

92 (24)

8 (2)

84 (22)

3 (1)

*	Data include adverse events of any grade that occurred during treatment (i.e., events reported during trial treatment or within 30 days after
the discontinuation of veliparib or placebo) in at least 20% of the safety population of 1124 patients (i.e., those who had received at least
one dose of a trial therapy) and corresponding adverse events of grade 3 or 4 that were assessed according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, version 4.03. Data are reported according to preferred terms in the Medical Dictionary for
Regulatory Activities, version 21.1. Grade 5 adverse events occurring within 30 days of the last dose of a trial drug were reported in 21 patients
(<2% overall; 6 patients in the control group, 7 in the veliparib-combination-only group, and 8 in the veliparib-throughout group) and included small-intestinal obstruction (in 2 patients), intestinal perforation (2), sepsis or septic shock (7), aspiration pneumonia (1), pulmonary embolism (2), and disease progression (7). The events of sepsis or septic shock occurred in 3 patients in the control group, 1 in the
veliparib-combination-only group, and 3 in the veliparib-throughout group.

grade serous ovarian carcinoma. Veliparib added
to chemotherapy led to a higher incidence of
anemia and thrombocytopenia and was generally
associated with nausea and fatigue but did not
adversely affect patients’ quality of life as reported
on surveys. The prolongation of progression-free
survival was seen across a broad population of
patients, including those with and those without
disease that was amenable to a primary surgical
cytoreduction attempt and those with and those
without an identifiable tumor feature that has
been associated with PARP inhibitor activity. A
response to chemotherapy was not needed for
2412
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inclusion in this trial, and progression-free survival was measured from randomization (start of
chemotherapy), in contrast to previous and contemporaneous trials of a PARP inhibitor used only
as maintenance therapy (PRIMA and PAOLA-1;
ClinicalTrials.gov numbers, NCT02655016 and
NCT02477644, respectively).17,38,39
An important consideration in treatment planning for primary chemotherapy is whether biomarker status is required for the selection of
treatment. We enrolled patients without regard to
biomarker status and evaluated veliparib in two
cohorts that were defined according to the pres-
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ence of germline or tissue-based BRCA mutations
and HRD status, as well as in the intention-to-treat
population. Results reported by Moore et al.17 had
established the safety and efficacy of PARP inhibitor maintenance therapy in patients with ovarian cancer with BRCA mutations, and the current
trial shows that the benefit of a PARP inhibitor
can be safely extended to all patients with newly
diagnosed ovarian cancer.
Few studies have combined PARP inhibitors
with standard chemotherapy doses for the treatment of ovarian cancer.22,40 Combining the two
classes of agents has a strong rationale on the basis of chemotherapy-induced DNA damage augmenting cellular reliance on DNA repair and
improving the efficacy of the PARP inhibitor. In
a large trial, olaparib was combined with paclitaxel and carboplatin therapy in women with recurrent, platinum-sensitive ovarian cancer.19 However, the carboplatin dose was reduced to an AUC
of 4 mg per milliliter per minute, and olaparib
was administered at a dose of 200 mg (in capsules) twice daily for 10 days of a 21-day cycle
(dose intensity, 24%). In the current trial, veliparib
was administered continuously during chemotherapy at a dose of 150 mg twice daily (dose intensity,
37.5%) with standard doses of carboplatin (AUC,
6 mg per milliliter per minute). Patients receiving
veliparib were still able to receive a high proportion
(84 to 93%) of all planned chemotherapy doses.
Adverse events that were reported with veliparib were predominantly gastrointestinal and hematologic. Veliparib added to chemotherapy led
to higher incidences of anemia and thrombocytopenia than were observed with chemotherapy
alone, although the incidences were significantly
lower during the maintenance phase, in which
less than 8% of the patients in the veliparibthroughout group had a grade 3 or 4 event. In
general, the incidence of toxic effects with veliparib monotherapy was lower than has been
reported with other PARP inhibitors.13,15-17
This trial was designed before the safety and
efficacy of PARP inhibitors in the context of maintenance therapy had been established. At the time,
we hypothesized that concurrent application of
agents with effects on DNA damage response in
patients who had not received chemotherapy previously would improve clinical outcomes. Results
from GOG-9923, a phase 1 trial that evaluated
veliparib with six regimens of platinum-based
chemotherapy and bevacizumab, confirmed that
n engl j med 381;25

veliparib could be safely administered with standard doses of chemotherapy.24
We designed this phase 3 trial to test the hypothesis that concurrent therapy with veliparib,
with or without veliparib maintenance therapy,
could improve progression-free survival among
patients with advanced ovarian cancer. The trial
design did not include a “veliparib maintenanceonly” group and therefore did not prospectively
address the relative contribution of maintenance
therapy with veliparib. Inferences drawn from
the absence of improvement in progression-free
survival in the veliparib-combination-only group
may suggest that the benefit from veliparib is
related to its use as maintenance therapy. If the
trial had incorporated a maintenance-only group
and shown results similar to those seen in the
veliparib-throughout group, the relative contributions of concurrent and maintenance veliparib
therapy in the veliparib-throughout group might
have been more definitively assessed. Nonetheless,
other historically successful strategies that incorporated concurrent and maintenance ther
apy into the context of first-line therapy (i.e.,
antiangiogenesis agents)4,5,41 have shown little
difference in progression-free survival during
the brief exposure before maintenance treatment.
In the current trial, less than 4% of the progression events occurred before the maintenance phase, which indicates that this measure
lacks sensitivity in the context of highly active
chemotherapy. As such, the hypothesis regarding concurrent therapy remains unproved.
In this phase 3, randomized, placebo-controlled
clinical trial involving patients with previously untreated advanced-stage ovarian cancer, veliparib
that was administered concomitantly with chemotherapy and continued as maintenance therapy
led to a moderately higher incidence of myelotoxic
and gastrointestinal toxic effects and resulted in
significantly longer progression-free survival than
induction chemotherapy without veliparib maintenance therapy.
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